| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 15.05.
| AB Science : Recruitment of the First Patient for the Phase 3 Study on Gleevec®-Resistant GIST, Comparing Masitinib with Sunitinib | | 54 | Business Wire |
| Postponement of communication on the results of the phase 3 study of
masitinib in pancreatic cancer
Authorization of a new phase 2 study in oncology, in head...
Mehr lesen zu:
AB Science : Recruitment of the First Patient for the Phase 3 Study on Gleevec®-Resistant GIST, Comparing Masitinib with Sunitinib | |
| 09.05.
| CORRECTING AND REPLACING: AB Science strengthens further its sources of financing through a PACEO® with Société Générale | | 38 | Business Wire |
| Regulatory News:
This replaces the announcement made at 5:45 p.m. CET on May 9, 2012 due
to the following corrections: Second graph, quote should read: "Even...
Mehr lesen zu:
CORRECTING AND REPLACING: AB Science strengthens further its sources of financing through a PACEO® with Société Générale | |
| 09.05.
| AB Science Strengthens Further Its Sources of Financing Through a PACEO® with Société Générale | | 51 | Business Wire |
| Regulatory News:
AB Science SA (Paris:AB)(Euronext Paris - FR0010557264 - AB), a
pharmaceutical company specialised in research, development and
commercialisation...
Mehr lesen zu:
AB Science Strengthens Further Its Sources of Financing Through a PACEO® with Société Générale | |
| 16.04.
| AB Science SA: Quarterly information – Jan-Mar 2012 | | 46 | Business Wire |
| Turnover up 10% compared to 2011 first quarter
€30 million in cash reserves
Regulatory News:
AB Science SA (Paris:AB)...
Mehr lesen zu:
AB Science SA: Quarterly information – Jan-Mar 2012 | |
| 05.03.
| AB Science issues 10 M€ in convertible bonds, at the reference price of 15.00 euros per share | | 51 | Business Wire |
| Regulatory News:
AB Science SA (Paris:AB)(NYSE Euronext - FR0010557264- AB), a
pharmaceutical company specialised in research, development and
commercialisation...
Mehr lesen zu:
AB Science issues 10 M€ in convertible bonds, at the reference price of 15.00 euros per share | |
| 22.02.
| AB Science Stock Eligible for SRD "Long-only" from February 24th 2012 | | 50 | Business Wire |
| Regulatory News:
AB Science (Paris:AB) announces that its stock will be eligible for SRD
"long-only"* on NYSE Euronext beginning Friday February 24th
...
Mehr lesen zu:
AB Science Stock Eligible for SRD "Long-only" from February 24th 2012 | |
| 20.02.
| AB Science: 2011 Annual Financial Results | | 69 | Business Wire |
| Regulatory News:
8 phase 3 and 9 phase 2 studies under way with masitinib
Encouraging survival results of masitinib vs. Sutent® in the
...
Mehr lesen zu:
AB Science: 2011 Annual Financial Results | |
| 01.02.
| AB Science Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival as compared to Pfizer's Sutent® in Gleevec®-resistant GIST | | 185 | Business Wire |
| Regulatory News:
AB Science SA (Paris:AB) (NYSE Euronext - FR0010557264 - AB)
today announced encouraging results from a phase 2 study with its
investigational...
Mehr lesen zu:
AB Science Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival as compared to Pfizer's Sutent® in Gleevec®-resistant GIST | |
| 15.12.
| AB Science: 2012 Publications | | 33 | Business Wire |
| Regulatory News:
Press releases are distributed before the opening of the stock market
February 20th
...
Mehr lesen zu:
AB Science: 2012 Publications | |
